Hydroxyethyl Starch

Identification

Name
Hydroxyethyl Starch
Accession Number
DB09106
Description

Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.

Type
Small Molecule
Groups
Approved
Synonyms
  • HAES
  • HES
  • Hetastarch
  • Hydroxyethylstarch

Pharmacology

Indication

An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

After isovolemic exchange of blood with 500 mL of HES in healthy volunteers, blood volume is maintained for at least 6 hours

Mechanism of action

Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. Recent studies have indicated that HES may reduce capillary leakage.

Absorption

Peak concentration (C(max), 4.34 mg/mL)

Volume of distribution

5.9 L.

Protein binding

Data not found.

Metabolism

When given intravenously, molecules smaller than the renal threshold (60,000-70,000 daltons) are readily and rapidly excreted in the urine, while molecules with higher molecular weights are metabolized by plasma α-amylase prior to excretion via the renal route.

Route of elimination

Approximately 62 % of HES was excreted as hydroxyethyl starch molecules in urine within 72 hours.

Half-life

Terminal half-life is 16.1 h. Elimination half-life is 12 h.

Clearance

31.4 mL/min

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LDF50 (IV, rabbit): 8460 mg/Kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
AcrivastineHydroxyethyl Starch may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
HextendSolution6 gIntravenousBiotime Inc2003-12-112013-07-12Canada flag
HextendInjection, solution6 g/100mLIntravenousHospira, Inc.2005-02-02Not applicableUS flag
VolulyteSolutionIntravenousFresenius Kabi2011-05-16Not applicableCanada flag
VoluvenSolution6 %IntravenousFresenius Kabi2006-09-18Not applicableCanada flag
VoluvenInjection, solution6 g/100mLIntravenousHospira, Inc.2010-06-252020-02-28US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
6% Hetastarch In 0.9% Sodium ChlorideInjection, solution6 g/100mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-11-26Not applicableUS flag
HetastarchInjection6 g/100mLIntravenousTeva Parenteral Medicines, Inc.2009-01-132014-09-30US flag
Hetastarch in Sodium ChlorideInjection, solution6 g/100mLIntravenousHospira, Inc.2005-02-28Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
HespanHydroxyethyl Starch (6 g/100mL) + Sodium chloride (0.9 g/100mL)Injection, solutionIntravenousB. Braun Medical Inc.1991-04-04Not applicableUS flag
HespanHydroxyethyl Starch (6 g/100mL) + Sodium chloride (0.9 g/100mL)Injection, solutionIntravenousCardinal Health1991-04-042016-03-31US flag
Hydroxyethyl Starch in Sodium ChlorideHydroxyethyl Starch (6 g/100mL) + Sodium chloride (900 mg/100mL)Injection, solutionIntravenousB. Braun Medical Inc.2015-01-09Not applicableUS flag

Categories

ATC Codes
B05AA07 — Hydroxyethylstarch
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
875Y4127EA
CAS number
9005-27-0
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
  1. Mutter TC, Ruth CA, Dart AB: Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2013 Jul 23;(7):CD007594. doi: 10.1002/14651858.CD007594.pub3. [PubMed:23881659]
  2. MSDS [Link]
KEGG Drug
D03335
PubChem Substance
347910407
RxNav
5531
ChEMBL
CHEMBL2108448
AHFS Codes
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticProstate Cancer1
4CompletedPreventionHypotension1
4CompletedPreventionPostoperative Cardiorespiratory Failure1
4CompletedTreatmentAbdominal Compartment Syndrome / Abdominal Hypertension / Severe Trauma1
4CompletedTreatmentArthroplasties, Hip Replacement1
4CompletedTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
4CompletedTreatmentCoronary Artery Bypass Grafting (CABG) / Valve Surgery1
4CompletedTreatmentCoronary Artery Disease (CAD) / Valvular Heart Disease1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentDelayed Bleeding / Post procedural complication / Post-Polypectomy Syndrome / Postoperative Hemorrhages1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntravenous10 %
SolutionIntravenous6 %
InjectionIntravenous
InjectionIntravenous6 g/100mL
Injection, solutionIntravenous6 g/100mL
SolutionIntravenous6 g
Injection, solutionIntravenous
Injection, solutionIntravenous60 g/1000ml
Injection, solutionIntravenous10 g/100mL
SolutionIntravenous6 g/100mL
Injection, solutionIntravenous30 g/500mL
SolutionIntravenous
Injection, solutionIntravenous60 g/1L
SolutionIntravenous0.9 g
Injection, solutionIntravenous10 %
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on September 16, 2015 16:43 / Updated on November 23, 2020 09:08

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates